Low uptake of seasonal influenza vaccination in Europe may jeopardise capacity to protect people in next pandemic
Influenza vaccination coverage among high-risk groups has dropped in the European Region over the last seven years, and half the countries report a decrease in the number of vaccine doses available.
Assessing seasonal influenza vaccine effectiveness
On 3 December 2015, ECDC hosts a technical meeting to discuss influenza vaccine effectiveness studies and how they can best meet public health needs as well as regulatory requirements.
Efficacy and safety of single and double doses of Ivermectin versus 7-day high dose Albendazole for chronic StrongyloidiasisArchived
A prospective, randomized, open study was conducted in which a 7-day course of oral albendazole 800 mg daily was compared with a single dose (200 microgram/kilogram body weight) or double doses, given 2 weeks apart, of ivermectin in Thai patients with chronic strongyloidiasis.
Influenza vaccine effectiveness: results of the ECDC/I-MOVE studies and other studiesArchived
On the 26 October 2011, The Lancet Infectious Diseases published a systematic review and a meta-analysis, combining the results of several studies undertaken on influenza vaccine effectiveness.
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines – (part 1)Archived
This is an authoritative independent evidence-based review and meta-analysis of the efficacy and effectiveness of influenza vaccines. It confines itself to trials and observational studies where diagnostic tests confirmed influenza infection as the end point.
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines – (part 2)Archived
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines
Overall and stratified estimates of influenza vaccine effectiveness in Europe for the season 2010-2011Archived
This paper gives the results from the third season of the ‘Influenza Monitoring Vaccine Effectiveness in Europe’ (I-MOVE) Project.
The importance of analyses of antigenic match and monitoring influenza vaccine effectivenessArchived
Influenza viruses pose a particular challenge for those designing vaccines for humans. Much of the protective immunity that humans have against these viruses following natural infection or vaccination is due to immunological recognition of the haemagglutinin (HA) surface glycoprotein.
Study shows decreased vaccine effectiveness of the seasonal influenza vaccine; ECDC Director urges to develop more effective vaccinesArchived
Preliminary results of European vaccine effectiveness study show decreased protective effect of the seasonal influenza vaccine in 2011/2012 season. ECDC Director Marc Sprenger calls for action.
Lower than usual: early influenza vaccine effectiveness in parts of Europe in season 2011/12Archived
A rapid communication published on April 12th 2012 describes the early results of the annual multicentre case-control study undertaken by the ECDC sponsored I-MOVE consortium whose work is coordinated by an Epiconcept team